The WuXi-backed investment firm returned for a series B2 round that will support phase 1/2 trials for iTeos Therapeutics' oncology therapies.

Autoimmune disease drug developer Pandion Therapeutics closed a series B round co-led by Access Biotechnology and backed by Roche Venture Fund and SR One.

The Parkinson's disease therapy developer closed the series A funding less than four months after a Eurofarma-backed seed round.

Intel Capital led a $14.1m round for the cancer diagnostics system provider, its parent company having already supplied it with artificial intelligence technology.

Based on research at Grousbeck Gene Therapy Center and Massachusetts Eye and Ear, Affinia has raised $60m in a series A round to advance its gene therapies into the clinic.

Lonza participated in the gene therapy developer's series A round alongside Partners Innovation Fund, having also licensed technology to the startup.

General Catalyst led a $51m round for the Ascension-backed healthcare automation technology developer, which has now received $119m in total.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Bpifrance supplied funding through three separate units to help take Satt Conectus-allied rare disease drug developer Dynacure's latest round to $55m.

Zucara Therapeutics, a diabetes treatment developer exploiting University of Toronto intellectual property, will use the money for phase 1 and 2 trials.